Ventyx Biosciences, Inc. 8-K

What Happened

• Ventyx Biosciences, Inc. (VTYX) filed an 8-K on Feb 23, 2026 providing supplemental disclosures to its Feb 2, 2026 definitive proxy about the proposed merger with Eli Lilly and Company.
• Under the Agreement and Plan of Merger dated Jan 7, 2026, each Ventyx common share outstanding at the merger’s Effective Time will be cancelled and converted into the right to receive $14.00 in cash (less withholding). Ventyx common stock will be delisted and no longer publicly traded if the merger closes.
• Regulatory progress: both companies filed HSR notifications on Jan 23, 2026; the HSR waiting period was terminated early on Feb 11, 2026 (initial waiting period would have expired Feb 23, 2026). Completion still requires other customary closing conditions.

Key Details

• Cash consideration: $14.00 per share to Ventyx stockholders.
• Fully diluted shares used in advisors’ analyses: ~85.354 million (as of Jan 5, 2026).
• Jefferies DCF: implied equity reference range $9.00–$10.60/share (discount rates 13.0%–15.0%), versus the $14.00 offer.
• Moelis assumptions and projections: discount/WACC range ~12.25%–15.00%; management projected NOL utilization of $51.8M (as of Dec 31, 2025); projections assumed an illustrative VTX3232 partnership (upfront $250M in 2026, 15% royalty, regulatory milestones of $500M and $200M for CV and Parkinson’s approvals in 2032).
• Litigation: two shareholder complaints filed in New York (Jones v. Ventyx, Feb 4, 2026; Kent v. Ventyx, Feb 5, 2026) alleging negligent misrepresentation/omission in the proxy; Ventyx says claims lack merit but additional suits or demand letters may be filed.
• Business-development background: after Oct 22, 2025 Phase 2 topline results for VTX3232, Ventyx contacted 16 large biopharma firms; 12 confidentiality agreements executed (Lilly, Sanofi and “Party A” among those conducting advanced due diligence); confidentiality agreements with Lilly, Party A and Sanofi did not contain standstill-like use restrictions.
• Executive employment: as of the proxy, no Ventyx executives have agreed to post‑merger employment/retention terms; Lilly proposals did not include employment offers for Ventyx executives.

Why It Matters

• For Ventyx shareholders: the deal offers $14 cash per share and would end public trading of Ventyx stock if completed. The price is above financial advisers’ standalone DCF ranges cited in the proxy, which may make the offer attractive to holders seeking certain cash value now.
• Regulatory and legal risks remain: early HSR termination is a positive step, but other closing conditions and potential antitrust or private lawsuits could delay or affect closing. Shareholder litigation alleging disclosure deficiencies could lead to injunctions or revised disclosures before a vote.
• Operational implications: projections underlying advisor analyses assume partnerships, milestone payments and specific launch timelines for Ventyx drug candidates; those assumptions and Ventyx’s NOLs affect valuation but are inherently uncertain. Executive employment terms are not finalized, which could affect retention of key personnel through closing.